Uncovering the roots of Parkinson's disease, together
A global basic research initiative
Aligning Science Across Parkinson’s (ASAP) is fostering collaboration and resources to better understand the underlying causes of Parkinson’s disease. With scale, transparency, and open access data sharing, we believe we can accelerate the pace of discovery, and inform the path to a cure.
ASAP Announces Protocol Particulars Series
ASAP has launched a new interview series where ASAP-funded researchers explain their protocols and share tips and best practices for utilizing them.
Collaborative Science Unlocks GBA1 Discovery
ASAP’s Managing Director Ekemini Riley reflects on the discovery of the first Parkinson’s disease genetic risk factor specific for African ancestry populations and highlights how GP2 is paving the way for impactful discoveries like this and more to come through its model of diverse, inclusive, and collaborative research.
New GBA Variant Linked to PD
Thanks in large part to the work of GP2 researchers, we are one step closer to understanding the genetic architecture of Parkinson’s Disease. Read our recently published article in The Lancet Neurology.
Latest News
Gene variant found linking people of African descent to higher Parkinson’s risk
Dr. Ekemini Riley, managing director of ASAP, joins PBS NewsHour to discuss findings from the GBA1 discovery and the power of collaborative, open science to unlock discoveries for populations traditionally underrepresented in research.
UNILAG researchers unravel novel Parkinson’s genetic risk factor in Africans
The Guardian Nigeria reports on GP2 and its collaboration with the University of Lagos (UNILAG) to uncover a genetic variant that increases the risk of PD in Africans and African admixed populations.
A Parkinson’s ‘game changer,’ backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments
STAT highlights how The Parkinson’s Progression Markers Initiative (PPMI) recently discovered how αSyn-SAA could be a novel tool for precision medicine approaches, earlier intervention, and improved clinical trial design for Parkinson’s disease.
